These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 21487042)
1. Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Milhollen MA; Narayanan U; Soucy TA; Veiby PO; Smith PG; Amidon B Cancer Res; 2011 Apr; 71(8):3042-51. PubMed ID: 21487042 [TBL] [Abstract][Full Text] [Related]
2. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. Blank JL; Liu XJ; Cosmopoulos K; Bouck DC; Garcia K; Bernard H; Tayber O; Hather G; Liu R; Narayanan U; Milhollen MA; Lightcap ES Cancer Res; 2013 Jan; 73(1):225-34. PubMed ID: 23100467 [TBL] [Abstract][Full Text] [Related]
3. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Luo Z; Yu G; Lee HW; Li L; Wang L; Yang D; Pan Y; Ding C; Qian J; Wu L; Chu Y; Yi J; Wang X; Sun Y; Jeong LS; Liu J; Jia L Cancer Res; 2012 Jul; 72(13):3360-71. PubMed ID: 22562464 [TBL] [Abstract][Full Text] [Related]
4. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Lin JJ; Milhollen MA; Smith PG; Narayanan U; Dutta A Cancer Res; 2010 Dec; 70(24):10310-20. PubMed ID: 21159650 [TBL] [Abstract][Full Text] [Related]
5. Destabilization of CDC6 upon DNA damage is dependent on neddylation but independent of Cullin E3 ligases. Tan CY; Hagen T Int J Biochem Cell Biol; 2013 Jul; 45(7):1489-98. PubMed ID: 23597704 [TBL] [Abstract][Full Text] [Related]
6. Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells. Lan H; Tang Z; Jin H; Sun Y Sci Rep; 2016 Apr; 6():24218. PubMed ID: 27063292 [TBL] [Abstract][Full Text] [Related]
7. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Brownell JE; Sintchak MD; Gavin JM; Liao H; Bruzzese FJ; Bump NJ; Soucy TA; Milhollen MA; Yang X; Burkhardt AL; Ma J; Loke HK; Lingaraj T; Wu D; Hamman KB; Spelman JJ; Cullis CA; Langston SP; Vyskocil S; Sells TB; Mallender WD; Visiers I; Li P; Claiborne CF; Rolfe M; Bolen JB; Dick LR Mol Cell; 2010 Jan; 37(1):102-11. PubMed ID: 20129059 [TBL] [Abstract][Full Text] [Related]
8. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. Jia L; Li H; Sun Y Neoplasia; 2011 Jun; 13(6):561-9. PubMed ID: 21677879 [TBL] [Abstract][Full Text] [Related]
9. WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells. Mackintosh C; García-Domínguez DJ; Ordóñez JL; Ginel-Picardo A; Smith PG; Sacristán MP; de Álava E Oncogene; 2013 Mar; 32(11):1441-51. PubMed ID: 22641220 [TBL] [Abstract][Full Text] [Related]
10. Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells. Wang Y; Luo Z; Pan Y; Wang W; Zhou X; Jeong LS; Chu Y; Liu J; Jia L Cancer Biol Ther; 2015; 16(3):420-9. PubMed ID: 25782162 [TBL] [Abstract][Full Text] [Related]
11. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Milhollen MA; Traore T; Adams-Duffy J; Thomas MP; Berger AJ; Dang L; Dick LR; Garnsey JJ; Koenig E; Langston SP; Manfredi M; Narayanan U; Rolfe M; Staudt LM; Soucy TA; Yu J; Zhang J; Bolen JB; Smith PG Blood; 2010 Sep; 116(9):1515-23. PubMed ID: 20525923 [TBL] [Abstract][Full Text] [Related]
12. CBS9106-induced CRM1 degradation is mediated by cullin ring ligase activity and the neddylation pathway. Saito N; Sakakibara K; Sato T; Friedman JM; Kufe DW; VonHoff DD; Kawabe T Mol Cancer Ther; 2014 Dec; 13(12):3013-23. PubMed ID: 25253782 [TBL] [Abstract][Full Text] [Related]
13. Deregulation of Cdt1 induces chromosomal damage without rereplication and leads to chromosomal instability. Tatsumi Y; Sugimoto N; Yugawa T; Narisawa-Saito M; Kiyono T; Fujita M J Cell Sci; 2006 Aug; 119(Pt 15):3128-40. PubMed ID: 16835273 [TBL] [Abstract][Full Text] [Related]
14. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Wei D; Li H; Yu J; Sebolt JT; Zhao L; Lawrence TS; Smith PG; Morgan MA; Sun Y Cancer Res; 2012 Jan; 72(1):282-93. PubMed ID: 22072567 [TBL] [Abstract][Full Text] [Related]
15. Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells. Luo Z; Pan Y; Jeong LS; Liu J; Jia L Autophagy; 2012 Nov; 8(11):1677-9. PubMed ID: 22874562 [TBL] [Abstract][Full Text] [Related]
16. Biochemical and cellular effects of inhibiting Nedd8 conjugation. Leck YC; Choo YY; Tan CY; Smith PG; Hagen T Biochem Biophys Res Commun; 2010 Jul; 398(3):588-93. PubMed ID: 20603103 [TBL] [Abstract][Full Text] [Related]
17. Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma. Benamar M; Guessous F; Du K; Corbett P; Obeid J; Gioeli D; Slingluff CL; Abbas T EBioMedicine; 2016 Aug; 10():85-100. PubMed ID: 27333051 [TBL] [Abstract][Full Text] [Related]
18. Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924. Liao H; Liu XJ; Blank JL; Bouck DC; Bernard H; Garcia K; Lightcap ES Mol Cell Proteomics; 2011 Nov; 10(11):M111.009183. PubMed ID: 21873567 [TBL] [Abstract][Full Text] [Related]
19. The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme. Yang D; Tan M; Wang G; Sun Y PLoS One; 2012; 7(3):e34079. PubMed ID: 22457814 [TBL] [Abstract][Full Text] [Related]
20. MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Nawrocki ST; Griffin P; Kelly KR; Carew JS Expert Opin Investig Drugs; 2012 Oct; 21(10):1563-73. PubMed ID: 22799561 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]